Vivid Dx raised $15M in seed funding to advance its pathogen detection platform and appointed Keith O'Neill as CEO to lead clinical validation and commercialization.
- Amount
- $15M
- Stage
- Seed
- Announced
- 28 July 2026
- Leads
- Oxford Science Enterprises, Cedars-Sinai Intellectual Property Co.
- Other investors
- Jameel Investment Management Company
- Use of funds
- Advance the platform through clinical validation toward commercialization, developing and testing its machine learning-enabled spectroscopic assay to cut sepsis testing times from days to hours.
- Checked
- Amount and date checked against the press source